Crestor Versus Placebo in Subjects With Heart Failure
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate if rosuvastatin, added on top of all other
medicines prescribed to subjects with symptomatic systolic heart failure, reduces the
combined endpoint of cardiovascular death or non-fatal myocardial infarction or non-fatal
stroke (time to first event)